PharmacyCodes



Atracurium Besylate en es it fr

Atracurium Besylate Brand names, Atracurium Besylate Analogs

Atracurium Besylate Brand Names Mixture

  • No information avaliable

Atracurium Besylate Chemical_Formula

C53H72N2O12+2

Atracurium Besylate RX_link

http://www.rxlist.com/cgi/generic2/trac.htm

Atracurium Besylate fda sheet

Atracurium Besylate msds (material safety sheet)

Atracurium_Besylate MSDS

Atracurium Besylate Synthesis Reference

No information avaliable

Atracurium Besylate Molecular Weight

929.145 g/mol

Atracurium Besylate Melting Point

185-194 oC

Atracurium Besylate H2O Solubility

Miscible

Atracurium Besylate State

Solid

Atracurium Besylate LogP

No information avaliable

Atracurium Besylate Dosage Forms

Injection (10mg/mL)

Atracurium Besylate Indication

For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Atracurium Besylate Pharmacology

Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.

Atracurium Besylate Absorption

No information avaliable

Atracurium Besylate side effects and Toxicity

Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.

Atracurium Besylate Patient Information

Atracurium Besylate Organisms Affected

Humans and other mammals